Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy

BackgroundHuman epidermal growth factor receptor 2(HER-2) is the most prominent therapeutic target for gastric (G)/gastroesophageal junction (GEJ) cancer.Guidelines recommend its use for treating G/GEJ cancers.However, targeted therapy did not significantly improve survival outcomes compared to those with neoadjuvant therapy.The KEYNOTE-811 trial r

read more

Parental style, adolescent children and hepatic transplantation

The biological, psychological and social developmental changes that occur during adolescence place the transplanted adolescent at an even higher risk of non-adherence and poor outcome than other age groups.Our aim is check whether parenting style influences the post-liver transplant outcome after liver transplantation.Participantsand Methods: Exige

read more